Stonegate Capital Partners has issued an updated research report on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company focused on developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The report highlights NeOnc's lead program, NEO212, a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy for brain cancer. NEO212 is engineered to address key limitations of current treatment, including BBB penetration and MGMT-driven resistance, which are major causes of treatment failure in glioblastoma (GBM) patients.
According to the update, NeOnc's platform includes NEO100 and NEO212. NEO212, an oral chemotherapy, aims to improve BBB penetration and overcome MGMT-driven resistance, targeting a large population where standard TMZ therapy frequently fails. The Phase 1 dose escalation study in recurrent GBM has completed, establishing a Recommended Phase 2 Dose of 610 mg, with early signs of disease control observed. This positions the program to advance into Phase 2 efficacy evaluation. NEO100, an intranasal therapy, offers a non-invasive drug delivery approach for recurrent GBM. Phase 2 data have shown radiographic responses and improved progression-free survival compared to historical salvage benchmarks.
Beyond its lead programs, NeOnc's platform combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. The company recently led a successful PIPE offering, adding a gross $16.0 million to its balance sheet, which provides financial runway for ongoing clinical development. For more details, view the full announcement here.
The updated coverage from Stonegate Capital Partners underscores the potential of NeOnc's innovative approach to CNS oncology. By addressing the critical challenge of drug delivery across the BBB, NeOnc's therapies could offer new hope for patients with brain tumors, particularly those who have failed standard treatments. The clinical momentum of NEO212 and NEO100, combined with the recent capital infusion, positions the company to advance its pipeline and potentially bring novel treatments to market.
